43 results on '"Sundberg, Berit"'
Search Results
2. Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition
3. Expansion of Gammadelta T Cells from Cord Blood: A Therapeutical Possibility
4. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue
5. Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease
6. Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?
7. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes
8. Treatment of Secondary Graft Failure after Hematopoietic Stem Cell Transplantation with Alpha/Beta T-Cell Depleted Grafts As Booster Infusions
9. Hypogammaglobulinemia in children after allogeneic hematopoietic stem cell transplantation: A cytokine mediated immunoglobulin isotype class switch arrest?
10. Hypogammaglobulinemia In Children Undergoing SCT: An Immunoglobulin Isotype Class Switch Arrest?
11. Human Embryonic Stem Cell-Derived Mesenchymal Stroma Cells (hES-MSCs) Engraft In Vivo and Support Hematopoiesis without Suppressing Immune Function: Implications for Off-The Shelf ES-MSC Therapies
12. Oral Mucosal Progenitor Cells Are Potently Immunosuppressive in a Dose-Independent Manner
13. One-year Follow-up of Tick-borne Central Nervous System Infections in Childhood
14. Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy
15. Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses
16. Multipotent Mesenchymal Stromal Cells Express FoxP3
17. Human Embryonic Stem Cell-Derived Mesenchymal Stroma Cells (hES-MSC) Share Basic Properties with Bone Marrow MSC, They Have Potent Stroma Support Capacities but Lack Immune-Modulatory Function. Implications for off-the Shelf ES-MSC Therapies.
18. Human Mesenchymal Stem Cells Elicit Complement Activation in Human Blood.
19. Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation: Results from a Prospective Study
20. Persistence of Human Parvovirus B19 in Multipotent Mesenchymal Stromal Cells Expressing the Erythrocyte P antigen: Implications for Transplantation
21. Complement activation triggered by human mesenchymal stem cells intended for clinical use
22. Persistence of Human Parvovirus B19 in Multipotent Mesenchymal Stromal Cells Expressing the Erythrocyte P Antigen: Implications for Transplantation
23. Novel Antibodies to the Donor Stem Cell Population CD34+/VEGFR-2+ Are Associated With Rejection After Hematopoietic Stem Cell Transplantation
24. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
25. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
26. Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.
27. Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.
28. Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
29. Inflammatory Cytokines Predominate in Cases of Tumor Regression after Hematopoietic Stem Cell Transplantation for Solid Cancer
30. Mesenchymal Stem Cells for Treatment of Severe Acute and Extensive Chronic Graft-Versus-Host Disease.
31. Decreased Serum Levels of Clara Cell Secretory Protein (CC16) Are Associated with Bronchiolitis Obliterans and May Permit Early Diagnosis in Patients after Allogeneic Stem-Cell Transplantation
32. Molecular monitoring of T‐cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II–IV
33. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
34. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells
35. A new in vitro model for the study of pig‐to‐human vascular hyperacute rejection
36. EXPRESSION OF COMPLEMENT REGULATORY PROTEINS ON ISLETS OF LANGERHANS: A COMPARISON BETWEEN HUMAN ISLETS AND ISLETS ISOLATED FROM NORMAL AND hDAF TRANSGENIC PIGS1
37. SOLUBLE COMPLEMENT RECEPTOR 1 (TP10) PRESERVES ADULT PORCINE ISLETS MORPHOLOGY AFTER INTRAPORTAL TRANSPLANTATION INTO CYNOMOLGUS MONKEYS.
38. IMMUNOSUPPRESSION WITH CsA, MMF AND LEFLUNOMIDE PREVENTS REJECTION FOR UP TO 100 DAYS AFTER ADULT PORCINE ISLET XENOTRANSPLANTATION INTO DIABETIC RATS.
39. FTY720 PLUS CsA INHIBITS PORCINE ISLET XENOGRAFT REJECTION IN RATS FOR UP TO 24 DAYS.
40. A COMPARISON OF FETAL AND ADULT PORCINE ISLETS WITH REGARD TO Gal?? (1,3)Gal EXPRESSION AND THE ROLE OF HUMAN IMMUNOGLOBULINS AND COMPLEMENT IN ISLET CELL CYTOTOXICITY1
41. DAMAGE TO PORCINE ISLETS OF LANGERHANS AFTER EXPOSURE TO HUMAN BLOOD IN VITRO, OR AFTER INTRAPORTAL TRANSPLANTATION TO CYNOMOLOGUS MONKEYS
42. PRETRANSPLANT HERPESVIRUS SEROLOGY AND ACUTE GRAFT-VERSUS-HOST DISEASE
43. T LYMPHOCYTE SUBPOPULATIONS IN BONE-MARROW-TRANSPLANTED PATIENTS IN RELATION TO GRAFT-VER8US-HOST DISEASE AND CYTOMEGALOVIRUS-INDUCEB INFECTION1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.